Bruker Corporation
BRKR US
BRKR USBruker Corporation
United States Composite85.75
USD
-1.83
(-2.09%)
- Business
- Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Company News
Bruker Subsidiary to Acquire TecInvest S.à r.l for $958M
These 20 growth stocks are worth considering on a pullback, says Citi
PhenomeX Shares Double After Bruker Buyout Offer
Bruker to Buy PhenomeX in $108 Million Deal
Bruker Corp To Acquire PhenomeX for $1 Per Shr in an All-Cash Transaction >BRKR
Bruker Corp 2Q EPS 39c >BRKR
GE HealthCare Techs Stock Earns 83 Relative Strength Rating
Bruker Board Approves Buyback for Up to $500M Over Two-Year Period
Bruker Announces New Two-Year Share Repurchase Authorization Of Up To $500 Million; Board Declares Quarterly Dividend >BRKR
Bruker Corp 1Q EPS 52c >BRKR
Shockwave Medical Stock With Rising Relative Strength
This SPAC Is Aligned With Shareholders. It's Merging With a Nuclear Services Firm.